JP2006509801A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006509801A5 JP2006509801A5 JP2004559142A JP2004559142A JP2006509801A5 JP 2006509801 A5 JP2006509801 A5 JP 2006509801A5 JP 2004559142 A JP2004559142 A JP 2004559142A JP 2004559142 A JP2004559142 A JP 2004559142A JP 2006509801 A5 JP2006509801 A5 JP 2006509801A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ethylsulfanylmethyl
- biphenyl
- phenoxy
- dimethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 20
- 125000003118 aryl group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000002877 alkyl aryl group Chemical group 0.000 claims 11
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000004429 atom Chemical group 0.000 claims 5
- 125000005647 linker group Chemical group 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N cycloheptane Chemical compound C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- -1 nitro, cyano, amino Chemical group 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 2
- 101150065749 Churc1 gene Proteins 0.000 claims 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 102100038239 Protein Churchill Human genes 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 2
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 150000001924 cycloalkanes Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 claims 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methylcyclopentane Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 239000001301 oxygen Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010022714 Intestinal ulcer Diseases 0.000 claims 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 210000005039 airway nerve Anatomy 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 238000013016 damping Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002183 duodenal effect Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- QDTQUWYRAOYVJL-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-2-[2-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)CCNC(=O)C1=CC=CC=C1C1=CC=CC=C1CSCCOC1=CC=CC=C1 QDTQUWYRAOYVJL-UHFFFAOYSA-N 0.000 claims 1
- FELYMTYTOAMZRM-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-2-[3-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;hydrochloride Chemical compound Cl.CN(C)CCNC(=O)C1=CC=CC=C1C1=CC=CC(CSCCOC=2C=CC=CC=2)=C1 FELYMTYTOAMZRM-UHFFFAOYSA-N 0.000 claims 1
- DKSIJMRGMKTNBR-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-2-[4-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)CCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CSCCOC1=CC=CC=C1 DKSIJMRGMKTNBR-UHFFFAOYSA-N 0.000 claims 1
- LNNOETJTMSDLFY-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-3-[2-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)CCNC(=O)C1=CC=CC(C=2C(=CC=CC=2)CSCCOC=2C=CC=CC=2)=C1 LNNOETJTMSDLFY-UHFFFAOYSA-N 0.000 claims 1
- MCNJPIUVSZGLLN-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-3-[4-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)CCNC(=O)C1=CC=CC(C=2C=CC(CSCCOC=3C=CC=CC=3)=CC=2)=C1 MCNJPIUVSZGLLN-UHFFFAOYSA-N 0.000 claims 1
- WUPJWBCAEKWGDY-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-4-[2-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide Chemical compound C1=CC(C(=O)NCCN(C)C)=CC=C1C1=CC=CC=C1CSCCOC1=CC=CC=C1 WUPJWBCAEKWGDY-UHFFFAOYSA-N 0.000 claims 1
- DLMBMQNMBCWDEE-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-4-[3-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide Chemical compound C1=CC(C(=O)NCCN(C)C)=CC=C1C1=CC=CC(CSCCOC=2C=CC=CC=2)=C1 DLMBMQNMBCWDEE-UHFFFAOYSA-N 0.000 claims 1
- GDKCWCCQFVKUNK-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]-4-[4-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC(C(=O)NCCN(C)C)=CC=C1C(C=C1)=CC=C1CSCCOC1=CC=CC=C1 GDKCWCCQFVKUNK-UHFFFAOYSA-N 0.000 claims 1
- LQOXGXQUSLMUTL-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-2-[2-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide Chemical compound CN(C)CCCNC(=O)C1=CC=CC=C1C1=CC=CC=C1CSCCOC1=CC=CC=C1 LQOXGXQUSLMUTL-UHFFFAOYSA-N 0.000 claims 1
- GLNGDYFLXUBPNG-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-2-[3-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide Chemical compound CN(C)CCCNC(=O)C1=CC=CC=C1C1=CC=CC(CSCCOC=2C=CC=CC=2)=C1 GLNGDYFLXUBPNG-UHFFFAOYSA-N 0.000 claims 1
- GHLHQSQJFBZQKJ-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-2-[4-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide Chemical compound CN(C)CCCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CSCCOC1=CC=CC=C1 GHLHQSQJFBZQKJ-UHFFFAOYSA-N 0.000 claims 1
- DZPPHBRORYQXPB-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-3-[2-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)CCCNC(=O)C1=CC=CC(C=2C(=CC=CC=2)CSCCOC=2C=CC=CC=2)=C1 DZPPHBRORYQXPB-UHFFFAOYSA-N 0.000 claims 1
- RWPAKUXYZGBFON-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-3-[3-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)CCCNC(=O)C1=CC=CC(C=2C=C(CSCCOC=3C=CC=CC=3)C=CC=2)=C1 RWPAKUXYZGBFON-UHFFFAOYSA-N 0.000 claims 1
- SPFYKPBABQCDFJ-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-3-[4-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)CCCNC(=O)C1=CC=CC(C=2C=CC(CSCCOC=3C=CC=CC=3)=CC=2)=C1 SPFYKPBABQCDFJ-UHFFFAOYSA-N 0.000 claims 1
- JUSRMRJMSMPGEH-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-4-[2-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide Chemical compound C1=CC(C(=O)NCCCN(C)C)=CC=C1C1=CC=CC=C1CSCCOC1=CC=CC=C1 JUSRMRJMSMPGEH-UHFFFAOYSA-N 0.000 claims 1
- AXCTUCCJQSBVCN-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-4-[3-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC(C(=O)NCCCN(C)C)=CC=C1C1=CC=CC(CSCCOC=2C=CC=CC=2)=C1 AXCTUCCJQSBVCN-UHFFFAOYSA-N 0.000 claims 1
- DZMFIABOJLTCQP-UHFFFAOYSA-N n-[3-(dimethylamino)propyl]-4-[4-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;hydrochloride Chemical compound Cl.C1=CC(C(=O)NCCCN(C)C)=CC=C1C(C=C1)=CC=C1CSCCOC1=CC=CC=C1 DZMFIABOJLTCQP-UHFFFAOYSA-N 0.000 claims 1
- FAOPHDMSPRHRBA-UHFFFAOYSA-N n-[4-(dimethylamino)butyl]-2-[2-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)CCCCNC(=O)C1=CC=CC=C1C1=CC=CC=C1CSCCOC1=CC=CC=C1 FAOPHDMSPRHRBA-UHFFFAOYSA-N 0.000 claims 1
- QDQOPHHTRAASDF-UHFFFAOYSA-N n-[4-(dimethylamino)butyl]-2-[3-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide Chemical compound CN(C)CCCCNC(=O)C1=CC=CC=C1C1=CC=CC(CSCCOC=2C=CC=CC=2)=C1 QDQOPHHTRAASDF-UHFFFAOYSA-N 0.000 claims 1
- MZVJGKABDKHPPE-UHFFFAOYSA-N n-[4-(dimethylamino)butyl]-2-[4-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)CCCCNC(=O)C1=CC=CC=C1C(C=C1)=CC=C1CSCCOC1=CC=CC=C1 MZVJGKABDKHPPE-UHFFFAOYSA-N 0.000 claims 1
- ZCWRVBROAACMAC-UHFFFAOYSA-N n-[4-(dimethylamino)butyl]-3-[2-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)CCCCNC(=O)C1=CC=CC(C=2C(=CC=CC=2)CSCCOC=2C=CC=CC=2)=C1 ZCWRVBROAACMAC-UHFFFAOYSA-N 0.000 claims 1
- NHKIIMBGHFZVTB-UHFFFAOYSA-N n-[4-(dimethylamino)butyl]-3-[4-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)CCCCNC(=O)C1=CC=CC(C=2C=CC(CSCCOC=3C=CC=CC=3)=CC=2)=C1 NHKIIMBGHFZVTB-UHFFFAOYSA-N 0.000 claims 1
- JCIWUZSRYDHNJP-UHFFFAOYSA-N n-[4-(dimethylamino)butyl]-4-[2-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide Chemical compound C1=CC(C(=O)NCCCCN(C)C)=CC=C1C1=CC=CC=C1CSCCOC1=CC=CC=C1 JCIWUZSRYDHNJP-UHFFFAOYSA-N 0.000 claims 1
- DMCRKRFTAIJUNA-UHFFFAOYSA-N n-[4-(dimethylamino)butyl]-4-[3-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC(C(=O)NCCCCN(C)C)=CC=C1C1=CC=CC(CSCCOC=2C=CC=CC=2)=C1 DMCRKRFTAIJUNA-UHFFFAOYSA-N 0.000 claims 1
- OGPHAGKFDHGOLT-UHFFFAOYSA-N n-[4-(dimethylamino)butyl]-4-[4-(2-phenoxyethylsulfanylmethyl)phenyl]benzamide;oxalic acid Chemical compound OC(=O)C(O)=O.C1=CC(C(=O)NCCCCN(C)C)=CC=C1C(C=C1)=CC=C1CSCCOC1=CC=CC=C1 OGPHAGKFDHGOLT-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- GJVFBWCTGUSGDD-UHFFFAOYSA-L pentamethonium bromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCC[N+](C)(C)C GJVFBWCTGUSGDD-UHFFFAOYSA-L 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000017497 prostate disease Diseases 0.000 claims 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229930192474 thiophene Natural products 0.000 claims 1
- 230000036269 ulceration Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43270102P | 2002-12-11 | 2002-12-11 | |
| PCT/US2003/037071 WO2004052848A1 (en) | 2002-12-11 | 2003-12-03 | Novel mch receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006509801A JP2006509801A (ja) | 2006-03-23 |
| JP2006509801A5 true JP2006509801A5 (enExample) | 2006-12-28 |
Family
ID=32507985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004559142A Withdrawn JP2006509801A (ja) | 2002-12-11 | 2003-12-03 | 新規ｍｃｈ受容体アンタゴニスト |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7132456B2 (enExample) |
| EP (1) | EP1572637A1 (enExample) |
| JP (1) | JP2006509801A (enExample) |
| CN (1) | CN1726189A (enExample) |
| AU (1) | AU2003302925A1 (enExample) |
| BR (1) | BR0316948A (enExample) |
| CA (1) | CA2509042A1 (enExample) |
| MX (1) | MXPA05006272A (enExample) |
| WO (1) | WO2004052848A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7446204B2 (en) | 2004-10-08 | 2008-11-04 | H. Lundbeck A/S | Amino substituted aryloxybenzylpiperidine derivatives |
| US7329656B2 (en) | 2004-10-08 | 2008-02-12 | H. Lundbeck A/S | Arylthiobenzylpiperidine derivatives |
| US7902356B2 (en) | 2004-12-17 | 2011-03-08 | Eli Lilly And Company | Thiazolopyridinone derivates as MCH receptor antagonists |
| CN101184732B (zh) * | 2005-03-28 | 2012-05-16 | 株式会社半导体能源研究所 | 蒽衍生物、发光元件用材料、发光元件、发光装置和电子器件 |
| US7731377B2 (en) * | 2006-03-21 | 2010-06-08 | Semiconductor Energy Laboratory Co., Ltd. | Backlight device and display device |
| US7772162B2 (en) | 2006-03-27 | 2010-08-10 | Board Of Regents, The University Of Texas System | Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells |
| US20070225176A1 (en) * | 2006-03-27 | 2007-09-27 | Pope Gary A | Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells |
| EP2402317B1 (en) * | 2006-03-31 | 2013-07-03 | Novartis AG | DGAT inhibitor |
| CN101522614B (zh) | 2006-08-09 | 2014-06-25 | 史密丝克莱恩比彻姆公司 | 作为阿片样物质受体的拮抗剂或反向激动剂的化合物 |
| CN101506163B (zh) * | 2006-08-30 | 2012-05-02 | 株式会社半导体能源研究所 | 合成蒽衍生物的方法和蒽衍生物、发光元件、发光装置、电子装置 |
| MX2009010091A (es) * | 2007-03-23 | 2010-02-17 | Univ Texas | Metodo para tratar una formacion de hidrocarburos. |
| CN101821305A (zh) * | 2007-03-23 | 2010-09-01 | 德克萨斯州立大学董事会 | 用溶剂处理地层的方法 |
| US7723722B2 (en) | 2007-03-23 | 2010-05-25 | Semiconductor Energy Laboratory Co., Ltd. | Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using anthracene derivative |
| US20080286445A1 (en) * | 2007-05-17 | 2008-11-20 | Semiconductor Energy Laboratory Co., Ltd. | Composition, and method of fabricating light-emitting element |
| AR066169A1 (es) * | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| MX2010005870A (es) * | 2007-11-30 | 2010-08-02 | Univ Texas | Metodos para mejorar la productividad de pozos productores de petroleo. |
| CN102089282A (zh) * | 2008-07-08 | 2011-06-08 | 株式会社半导体能源研究所 | 咔唑衍生物、发光元件用材料、发光元件以及发光装置 |
| EP2166001B1 (en) * | 2008-09-19 | 2011-07-20 | Semiconductor Energy Laboratory Co., Ltd. | Carbazole Derivative and Method for Producing the Same |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| JP5557845B2 (ja) | 2008-10-31 | 2014-07-23 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体 |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| MX348131B (es) | 2011-02-25 | 2017-05-26 | Merck Sharp & Dohme | Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos. |
| WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| KR102844041B1 (ko) | 2016-02-26 | 2025-08-11 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 유기 화합물, 발광 소자, 발광 장치, 전자 기기, 및 조명 장치 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298B1 (en) | 2016-12-20 | 2026-03-11 | Merck Sharp & Dohme LLC | Antidiabetic spirochroman compounds |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| KR102708681B1 (ko) | 2018-02-13 | 2024-09-26 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP4600247A3 (en) | 2018-04-19 | 2025-11-19 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| UA126421C2 (uk) | 2018-07-13 | 2022-09-28 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| CN121925305A (zh) | 2023-11-09 | 2026-04-24 | 切弗朗菲利浦化学公司 | 用于铬催化剂活化的系统和方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3535330A (en) * | 1968-04-29 | 1970-10-20 | Sandoz Ag | 2,6-diphenyl - 4 - (p-(dilower-alkyl amino lower - alkoxy)phenyl)pyridines and derivatives thereof |
| US3928449A (en) * | 1969-04-03 | 1975-12-23 | Sandoz Ag | Aminoalkoxy-terphenyls and the salts thereof |
| LU78484A1 (de) * | 1977-11-10 | 1979-06-13 | Ciba Geigy Ag | Verfahren zur herstellung von benzoxazolyl-phenyl-stilbenen |
| DE2752361A1 (de) | 1977-11-24 | 1979-06-07 | Troponwerke Gmbh & Co Kg | Neue indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| US7115750B1 (en) | 1999-09-20 | 2006-10-03 | Takeda Pharmaceutical Company Limited | Melanin concentrating hormone antagonist |
-
2003
- 2003-12-03 AU AU2003302925A patent/AU2003302925A1/en not_active Abandoned
- 2003-12-03 CA CA002509042A patent/CA2509042A1/en not_active Abandoned
- 2003-12-03 MX MXPA05006272A patent/MXPA05006272A/es unknown
- 2003-12-03 CN CNA2003801059746A patent/CN1726189A/zh active Pending
- 2003-12-03 BR BR0316948-0A patent/BR0316948A/pt not_active Application Discontinuation
- 2003-12-03 WO PCT/US2003/037071 patent/WO2004052848A1/en not_active Ceased
- 2003-12-03 US US10/536,053 patent/US7132456B2/en not_active Expired - Fee Related
- 2003-12-03 JP JP2004559142A patent/JP2006509801A/ja not_active Withdrawn
- 2003-12-03 EP EP03812783A patent/EP1572637A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005529923A5 (enExample) | ||
| CN102119152B (zh) | 有机化合物 | |
| KR20200118062A (ko) | 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용 | |
| ZA200504822B (en) | 1,5,-Diaryl-pyrrole-3-carboxamide derivatives and their us as cannabinoid receptor modulators | |
| JP2007500716A5 (enExample) | ||
| EP1799664A1 (en) | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | |
| RU2005105053A (ru) | Новые производные пиперидина для применения в лечении болезненных состояний, опосредованных хемокинами | |
| JP2006524222A5 (enExample) | ||
| EP1536797A1 (en) | 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related comounds as neurokinin-1 (nk-1) antagonsists for the treatment of emesis, depression, anxiety and cough | |
| AU2003290280A1 (en) | 4, 5-diarylthiazole derivatives as cb-1 ligands | |
| JP2009544620A (ja) | 自己免疫疾患及び炎症のためのプロリン尿素ｃｃｒ１アンタゴニスト | |
| KR950704328A (ko) | 5-HT₄ 수용체 길항제로서의 피페리딘 유도체(Piperidine Derivatives as 5-HT₄ Receptor Antagonists) | |
| WO1993016048A1 (fr) | Compose d'acetamide substitue | |
| RU2007101685A (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
| BG62138B1 (bg) | Арилглицинамидни производни, метод за получаването им ифармацевтични състави, които ги съдържат | |
| CA2674548A1 (en) | Novel n-(2-aminophenyl) benzamide derivative having urea structure | |
| EP2414366A1 (en) | Spiro derivatives for the modulation of stearoyl-coa desaturase | |
| CA3208103A1 (en) | Anti-viral compounds | |
| RU2009146124A (ru) | Дигидрохиноновые и дигидронафтиридиновые ингибиторы киназы jnk | |
| CN105693597A (zh) | 新的亲环素抑制剂及其用途 | |
| JP2008524249A5 (enExample) | ||
| KR19980703476A (ko) | 피롤리딘일 하이드록삼산 화합물 및 그의 제조 방법 | |
| RU2006130686A (ru) | Новые пиперидины в качестве модуляторов хемокинов (ccr) | |
| WO2012038904A1 (fr) | Derives de nicotinamide, leur preparation et leur application en therapeutique | |
| CN118791481A (zh) | 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用 |